Adalimumab

Alternative Names: Humira

Adalimumab is an FDA-approved biologic treatment for moderate to severe hidradenitis suppurativa. It is a tumor necrosis factor-alpha (TNF-α) inhibitor that works by blocking inflammatory pathways responsible for HS lesions. Adalimumab is given as a subcutaneous injection. Clinical trials have shown it can reduce the number of abscesses and inflammatory nodules, decrease pain, and improve quality of life. Common side effects include injection site reactions and increased risk of infection, so screening for tuberculosis and hepatitis B is required before starting therapy.

Treatment Type: Prescription Medication

Treatment Class: Anti TNF alpha

Treatment Modality: Injection

Adalimumab

Review Summary

5.0

1 Reviews

Preferred by 1 Reviewers

Based on the review by Dr. Curbside, Adalimumab appears to be an effective first-line systemic treatment for moderate to severe hidradenitis suppurativa. By blocking TNF-α, it helps reduce inflammation, painful symptoms, and the frequency of disease flares. The treatment is rated 3 out of a possible rating scale, suggesting moderate effectiveness.

This summary was generated by users' reviews

Breakdown by Category

Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.

Cost
1.0
1 = Very Expensive 5 = Very Affordable

1.0

Very Expensive
Relief Speed
2.0
1 = No Relief 5 = Immediate Relief

2.0

Slow Relief
Side Effects
4.0
1 = Intolerable Effect 5 = No Effect

4.0

Mild Effect
Treatment Line
1.0
1 = Third-line or more 5 = First-line

1.0

Third-line or more

Explore various treatment options to empower yourself in making a well-informed choice.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

5.0

1 Reviews
5
100%
4
0%
3
0%
2
0%
1
0%

AI Summary of User Experiences

Not medical advice.

Based on the review by Dr. Curbside, Adalimumab appears to be an effective first-line systemic treatment for moderate to severe hidradenitis suppurativa. By blocking TNF-α, it helps reduce inflammation, painful symptoms, and the frequency of disease flares. The treatment is rated 3 out of a possible rating scale, suggesting moderate effectiveness.

Reviews

Filter by reviewer type Pro

Select all Clear all

Cost
Very Expensive
$1000+
Expensive
$501 to $1000
Moderate Cost
$101 to $500
Affordable
$25 to $100
Very Affordable
$25
Relief Speed
No Relief
No noticeable improvement
Slow Relief
Several days to weeks
Moderate Relief
Within 1 - 3 days
Fast Relief
Within hours
Immediate Relief
Within minutes
Side Effect
Intolerable Side Effect
Caused treatment to stop or required hospitalization
Severe Side Effect
Difficult to tolerate, may require intervention
Moderate Side Effect
Noticeable, but manageable
Mild Side Effect
Minor, not bothersome
No Side Effect
Without any adverse effects
Treatment Line
Third-line or more
Used after second-line failed or multiple prior treatment
Second-line
Used after first-line treatment failed or was unsuitable
First-line
First treatment tried
Dr. Curbside

Dr. Curbside

Verified
Physician • Emergency Medicine • How doctors think about decisions — and what real-world experiences add
2 months ago
Adalimumab is a first-line systemic therapy for moderate to severe hidradenitis suppurativa. It blocks tumor necrosis factor-alpha (TNF-α), a key driver of inflammation in HS, helping to reduce painful nodules, abscesses, and flare frequency.
#VeryExpensive #CoveredByInsurance #SlowRelief #MildEffect #Third-lineOrMore #Maintenance #Rescue/EmergencyUse #Preventative
View Professional Disclosures

Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.

We use cookies to personalize our services and provide you with the best possible experience. By continuing to use this site, you agree to this cookie usage. We also use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent. You can learn more about cookies and how your data is processed in the Privacy Policy.

Strictly Necessary Only Accept All